United States · FDA National Drug Code directory
Rizatriptan Benzoate
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 65862-625_b813e372-4315-4a35-a6dd-592b69aee7b8
- Product NDC
- 65862-625
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Rizatriptan Benzoate
- Labeler
- Aurobindo Pharma Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20130701
- Source listing expiry
- 20261231
Source-listed ingredients
- RIZATRIPTAN BENZOATE — 5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 4 BLISTER PACK in 1 CARTON (65862-625-12) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (65862-625-03) · 65862-625-12
- 3 BLISTER PACK in 1 CARTON (65862-625-18) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (65862-625-06) · 65862-625-18
- 9 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-625-36) · 65862-625-36
- 18 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-625-48) · 65862-625-48
- 1 BLISTER PACK in 1 CARTON (65862-625-64) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (65862-625-03) · 65862-625-64
- 3 BLISTER PACK in 1 CARTON (65862-625-90) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (65862-625-03) · 65862-625-90
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →